Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
- 22 August 2010
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 17 (1), 2-10
- https://doi.org/10.1111/j.1365-2516.2010.02370.x
Abstract
The pharmacokinetic (PK) response to factor VIII (FVIII) and factor IX varies between patients and this has important clinical implications for treatment. Although PK is affected by patient characteristics, this relationship is too weak to infer a result for an individual and, if required, PK must be measured. An important determinant of the efficacy of prophylaxis is the length of time an individual spends with a low level of coagulation factor. This time is more dependent on the patient's coagulation factor half-life and the frequency of dosing than in vivo recovery and dose infused. Improved understanding of the effect of PK and dose frequency on factor levels in patients on prophylaxis will help tailor regimens to individuals better and allow more cost effective use of coagulation factor concentrates. Calculations suggest that adults need less FVIII per kg body weight than children. The effect of half-life on trough levels questions the logic of Monday, Wednesday, Friday dosing and suggests a role for innovative regimens including low-dose daily treatment which leads to either higher trough levels or decreased FVIII requirement. This may expand access to prophylaxis in healthcare systems with limited resources and potentially improve patient outcomes. The ideal trough level will vary between individuals and at different times of their lives and may be <1 IU dL(-1). If PK is to be used in routine clinical practice, a simplified method for its measurement is required and this methodology is becoming available.Keywords
This publication has 50 references indexed in Scilit:
- Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoringJournal of Thrombosis and Haemostasis, 2010
- Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJournal of Thrombosis and Haemostasis, 2008
- Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII – an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophiliaHaemophilia, 2006
- Pharmacokinetic studies: international guidelines for the conduct and interpretation of such studiesHaemophilia, 2006
- Variability in clinical phenotype of severe haemophilia: the role of the first joint bleedHaemophilia, 2005
- Use of recombinant factor IX in subjects with haemophilia B undergoing surgeryHaemophilia, 2002
- Pharmacokinetics of Coagulation FactorsClinical Pharmacokinetics, 2001
- Pharmacokinetics of Factor VIII in HumansClinical Pharmacokinetics, 1992
- Clinical Pharmacokinetics of Factor VIII in Patients with Classic HaemophiliaClinical Pharmacokinetics, 1987
- A calculator program for clinical application of the Bayesian method of predicting plasma drug levelsComputer Programs in Biomedicine, 1985